GT101 + HUMAN INTERLEUKIN-2 for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Feb 2024: Trial registered, NCT06241781
  2. 2 Apr 2024: Trial started, NCT06241781

The trials

NCT06241781: Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer

State
Under way
Phase
Phase 2
People
100 planned
Started
2 Apr 2024
Primary completion
31 Jan 2027
Arms
GT101 treatment group
Results
None posted
  1. 5 Feb 2024: Trial registered
  2. 2 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.